Aidan Power

816 total citations · 1 hit paper
25 papers, 554 citations indexed

About

Aidan Power is a scholar working on Physiology, Psychiatry and Mental health and Pharmacology. According to data from OpenAlex, Aidan Power has authored 25 papers receiving a total of 554 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Physiology, 9 papers in Psychiatry and Mental health and 8 papers in Pharmacology. Recurrent topics in Aidan Power's work include Alzheimer's disease research and treatments (15 papers), Dementia and Cognitive Impairment Research (8 papers) and Cholinesterase and Neurodegenerative Diseases (7 papers). Aidan Power is often cited by papers focused on Alzheimer's disease research and treatments (15 papers), Dementia and Cognitive Impairment Research (8 papers) and Cholinesterase and Neurodegenerative Diseases (7 papers). Aidan Power collaborates with scholars based in United States, Czechia and United Kingdom. Aidan Power's co-authors include John A. Hey, Susan Abushakra, Martin Tolar, Josef Bäuml, Werner Kissling, Steven R. Hirsch, Yongxin Yu, Petr Kočiš, Mark Versavel and Paul L. Kaplan and has published in prestigious journals such as JAMA, PLoS ONE and Neurology.

In The Last Decade

Aidan Power

23 papers receiving 533 citations

Hit Papers

Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pa... 2021 2026 2022 2024 2021 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression
    2021 145 citations Martin Tolar, John A. Hey et al. International Journal of Molecular Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aidan Power United States 11 282 176 175 127 88 25 554
L. S. Schneider United States 7 284 1.0× 178 1.0× 185 1.1× 123 1.0× 92 1.0× 9 673
W. James Deardorff United States 11 166 0.6× 132 0.8× 194 1.1× 164 1.3× 61 0.7× 31 670
Kasia Lobello United States 8 112 0.4× 116 0.7× 146 0.8× 50 0.4× 39 0.4× 10 434
Bernd Ibach Germany 18 300 1.1× 282 1.6× 168 1.0× 121 1.0× 73 0.8× 46 861
Ying Tian United States 10 429 1.5× 167 0.9× 165 0.9× 138 1.1× 90 1.0× 22 686
Yvonne Wirth Germany 8 234 0.8× 321 1.8× 278 1.6× 70 0.6× 51 0.6× 12 716
Bart Laurijssens United States 10 147 0.5× 143 0.8× 62 0.4× 84 0.7× 47 0.5× 15 560
Miquel Baquero Spain 9 151 0.5× 91 0.5× 78 0.4× 65 0.5× 39 0.4× 17 362
Vishakantha Murthy United States 10 92 0.3× 102 0.6× 74 0.4× 191 1.5× 31 0.4× 27 630
Martin Farlow United States 6 180 0.6× 189 1.1× 301 1.7× 110 0.9× 67 0.8× 10 565

Countries citing papers authored by Aidan Power

Since Specialization
Citations

This map shows the geographic impact of Aidan Power's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aidan Power with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aidan Power more than expected).

Fields of papers citing papers by Aidan Power

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aidan Power. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aidan Power. The network helps show where Aidan Power may publish in the future.

Co-authorship network of co-authors of Aidan Power

This figure shows the co-authorship network connecting the top 25 collaborators of Aidan Power. A scholar is included among the top collaborators of Aidan Power based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aidan Power. Aidan Power is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hey, John A., Yongxin Yu, Susan Abushakra, et al.. (2025). Clinical Pharmacokinetics of Oral ALZ-801/Valiltramiprosate in a 2-Year Phase 2 Trial of APOE4 Carriers with Early Alzheimer’s Disease. Clinical Pharmacokinetics. 64(3). 407–424. 1 indexed citations
2.
3.
Tolar, Martin, John A. Hey, Aidan Power, & Susan Abushakra. (2024). The Single Toxin Origin of Alzheimer’s Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention. International Journal of Molecular Sciences. 25(5). 2727–2727. 12 indexed citations
4.
5.
Abushakra, Susan, Anton P. Porsteinsson, Marwan Sabbagh, et al.. (2024). APOLLOE4 Phase 3 study of oral ALZ‐801/valiltramiprosate in APOE ε4/ε4 homozygotes with early Alzheimer's disease: Trial design and baseline characteristics. Alzheimer s & Dementia Translational Research & Clinical Interventions. 10(3). e12498–e12498. 10 indexed citations
6.
7.
Hey, John D., Susan Abushakra, Kaj Blennow, et al.. (2023). Effects of ALZ-801, an Oral Amyloid Oligomer Inhibitor, on Biomarkers of Alzheimer’s Disease (AD): 12-Month Results of Phase 2 Biomarker Study in Early AD (S26.007). Neurology. 100(17_supplement_2). 2 indexed citations
8.
9.
Power, Aidan, et al.. (2022). Medical student wellness assessment beyond anxiety and depression: A scoping review. PLoS ONE. 17(10). e0276894–e0276894. 13 indexed citations
10.
Tolar, Martin, John A. Hey, Aidan Power, & Susan Abushakra. (2021). Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression. International Journal of Molecular Sciences. 22(12). 6355–6355. 145 indexed citations breakdown →
11.
Hey, John A., Petr Kočiš, Jakub Hort, et al.. (2018). Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain. CNS Drugs. 32(9). 849–861. 47 indexed citations
12.
Power, Aidan. (2018). Contemporary European Science Fiction Cinemas. 2 indexed citations
13.
Hey, John A., Yongxin Yu, Mark Versavel, et al.. (2017). Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease. Clinical Pharmacokinetics. 57(3). 315–333. 93 indexed citations
14.
15.
Power, Aidan, Adam C. Berger, & Geoffrey S. Ginsburg. (2014). Genomics-Enabled Drug Repositioning and Repurposing. JAMA. 311(20). 2063–2063. 26 indexed citations
16.
Power, Aidan. (2014). Zoom in, zoom out: crossing borders in contemporary European cinema. Studies in European Cinema. 12(2). 176–179. 2 indexed citations
17.
18.
Johnson, Keith, et al.. (2006). Race and Ethnicity in the Era of Emerging Pharmacogenomics. The Journal of Clinical Pharmacology. 46(4). 405–407. 20 indexed citations
19.
Johnson, Keith, John F. Thompson, & Aidan Power. (2005). Pharmacogenomics: Integration into Drug Discovery and Development. Current Topics in Medicinal Chemistry. 5(11). 1039–1046. 3 indexed citations
20.
Hirsch, Steven R., et al.. (2002). A 28-Week Comparison of Ziprasidone and Haloperidol in Outpatients With Stable Schizophrenia. The Journal of Clinical Psychiatry. 63(6). 516–523. 119 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L. S. Schneider Breakdown of academic impact, for papers by W. James Deardorff Breakdown of academic impact, for papers by Kasia Lobello Breakdown of academic impact, for papers by Bernd Ibach Breakdown of academic impact, for papers by Ying Tian Breakdown of academic impact, for papers by Yvonne Wirth Breakdown of academic impact, for papers by Bart Laurijssens Breakdown of academic impact, for papers by Miquel Baquero Breakdown of academic impact, for papers by Vishakantha Murthy Breakdown of academic impact, for papers by Martin Farlow
Rankless by CCL
2026